Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs

Detalhes bibliográficos
Autor(a) principal: Albuquerque, Denilson C.
Data de Publicação: 2005
Outros Autores: Miziara, Lineu J., Saraiva, Jose F. K., Rodrigues, Ulisses S., Ribeiro, Artur B. [UNIFESP], Wajngarten, Mauricio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S1677-55382005000400008
http://repositorio.unifesp.br/handle/11600/2593
Resumo: OBJECTIVE: To evaluate the efficacy, safety and tolerability of sildenafil among Brazilian patients with hypertension treated with combinations of anti-hypertensive drugs. MATERIALS AND METHODS: One hundred twenty hypertensive men aged 30 to 81 years old under treatment with 2 or more anti-hypertensive drugs and with erectile dysfunction (ED) lasting for at least 6 months were enrolled at 7 research centers in Brazil. Patients were randomized to receive treatment with either sildenafil or placebo taken 1 hour before sexual intercourse (initial dose of 50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity). During the following 8 weeks, patients were evaluated regarding vital signs, adverse events, therapeutic efficacy, satisfaction with treatment and use of concurrent medications. RESULTS: The primary evaluation of efficacy, which was based on responses to questions 3 and 4 of the International Index of Erectile Function, showed significant differences regarding treatment with sildenafil (p = 0.0002 and p < 0.0001, respectively). In the assessment of global efficacy, 87% of the patients treated with sildenafil reported improved erections, as compared with 37% of patients given placebos (p < 0.0001). The other secondary evaluations supported the results favoring sildenafil. The most frequent adverse events among patients treated with sildenafil were headaches (11.4%), vasodilation (11.4%) and dyspepsia (6.5%). There were no significant changes in blood pressure measurements in both groups. CONCLUSION: Sildenafil is efficacious and safe for the treatment of hypertensive patients with ED who receive concurrent combinations of anti-hypertensive drugs.
id UFSP_ea256afc9601e645a510ec3982e93f4a
oai_identifier_str oai:repositorio.unifesp.br/:11600/2593
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugserectile dysfunctionsildenafilhypertensionanti-hypertensivedrugsOBJECTIVE: To evaluate the efficacy, safety and tolerability of sildenafil among Brazilian patients with hypertension treated with combinations of anti-hypertensive drugs. MATERIALS AND METHODS: One hundred twenty hypertensive men aged 30 to 81 years old under treatment with 2 or more anti-hypertensive drugs and with erectile dysfunction (ED) lasting for at least 6 months were enrolled at 7 research centers in Brazil. Patients were randomized to receive treatment with either sildenafil or placebo taken 1 hour before sexual intercourse (initial dose of 50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity). During the following 8 weeks, patients were evaluated regarding vital signs, adverse events, therapeutic efficacy, satisfaction with treatment and use of concurrent medications. RESULTS: The primary evaluation of efficacy, which was based on responses to questions 3 and 4 of the International Index of Erectile Function, showed significant differences regarding treatment with sildenafil (p = 0.0002 and p < 0.0001, respectively). In the assessment of global efficacy, 87% of the patients treated with sildenafil reported improved erections, as compared with 37% of patients given placebos (p < 0.0001). The other secondary evaluations supported the results favoring sildenafil. The most frequent adverse events among patients treated with sildenafil were headaches (11.4%), vasodilation (11.4%) and dyspepsia (6.5%). There were no significant changes in blood pressure measurements in both groups. CONCLUSION: Sildenafil is efficacious and safe for the treatment of hypertensive patients with ED who receive concurrent combinations of anti-hypertensive drugs.State University of Rio de Janeiro Department of CardiologyFederal University of Uberlandia Department of CardiologyPontifical Catholic University Department of CardiologySalgado Filho Hospital Department of General PracticeFederal University of São Paulo Department of NephrologyInstitute of Heart CardioGeriatry ServiceUNIFESP, Department of NephrologySciELOSociedade Brasileira de UrologiaState University of Rio de Janeiro Department of CardiologyFederal University of Uberlandia Department of CardiologyPontifical Catholic University Department of CardiologySalgado Filho Hospital Department of General PracticeUniversidade Federal de São Paulo (UNIFESP)Institute of Heart CardioGeriatry ServiceAlbuquerque, Denilson C.Miziara, Lineu J.Saraiva, Jose F. K.Rodrigues, Ulisses S.Ribeiro, Artur B. [UNIFESP]Wajngarten, Mauricio2015-06-14T13:31:39Z2015-06-14T13:31:39Z2005-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion342-355application/pdfhttp://dx.doi.org/10.1590/S1677-55382005000400008International braz j urol. Sociedade Brasileira de Urologia, v. 31, n. 4, p. 342-355, 2005.10.1590/S1677-55382005000400008S1677-55382005000400008.pdf1677-5538S1677-55382005000400008http://repositorio.unifesp.br/handle/11600/2593engInternational braz j urolinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-04T14:07:42Zoai:repositorio.unifesp.br/:11600/2593Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-04T14:07:42Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
title Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
spellingShingle Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
Albuquerque, Denilson C.
erectile dysfunction
sildenafil
hypertension
anti-hypertensive
drugs
title_short Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
title_full Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
title_fullStr Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
title_full_unstemmed Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
title_sort Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs
author Albuquerque, Denilson C.
author_facet Albuquerque, Denilson C.
Miziara, Lineu J.
Saraiva, Jose F. K.
Rodrigues, Ulisses S.
Ribeiro, Artur B. [UNIFESP]
Wajngarten, Mauricio
author_role author
author2 Miziara, Lineu J.
Saraiva, Jose F. K.
Rodrigues, Ulisses S.
Ribeiro, Artur B. [UNIFESP]
Wajngarten, Mauricio
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv State University of Rio de Janeiro Department of Cardiology
Federal University of Uberlandia Department of Cardiology
Pontifical Catholic University Department of Cardiology
Salgado Filho Hospital Department of General Practice
Universidade Federal de São Paulo (UNIFESP)
Institute of Heart CardioGeriatry Service
dc.contributor.author.fl_str_mv Albuquerque, Denilson C.
Miziara, Lineu J.
Saraiva, Jose F. K.
Rodrigues, Ulisses S.
Ribeiro, Artur B. [UNIFESP]
Wajngarten, Mauricio
dc.subject.por.fl_str_mv erectile dysfunction
sildenafil
hypertension
anti-hypertensive
drugs
topic erectile dysfunction
sildenafil
hypertension
anti-hypertensive
drugs
description OBJECTIVE: To evaluate the efficacy, safety and tolerability of sildenafil among Brazilian patients with hypertension treated with combinations of anti-hypertensive drugs. MATERIALS AND METHODS: One hundred twenty hypertensive men aged 30 to 81 years old under treatment with 2 or more anti-hypertensive drugs and with erectile dysfunction (ED) lasting for at least 6 months were enrolled at 7 research centers in Brazil. Patients were randomized to receive treatment with either sildenafil or placebo taken 1 hour before sexual intercourse (initial dose of 50 mg, adjusted to 25 mg or 100 mg according to efficacy and toxicity). During the following 8 weeks, patients were evaluated regarding vital signs, adverse events, therapeutic efficacy, satisfaction with treatment and use of concurrent medications. RESULTS: The primary evaluation of efficacy, which was based on responses to questions 3 and 4 of the International Index of Erectile Function, showed significant differences regarding treatment with sildenafil (p = 0.0002 and p < 0.0001, respectively). In the assessment of global efficacy, 87% of the patients treated with sildenafil reported improved erections, as compared with 37% of patients given placebos (p < 0.0001). The other secondary evaluations supported the results favoring sildenafil. The most frequent adverse events among patients treated with sildenafil were headaches (11.4%), vasodilation (11.4%) and dyspepsia (6.5%). There were no significant changes in blood pressure measurements in both groups. CONCLUSION: Sildenafil is efficacious and safe for the treatment of hypertensive patients with ED who receive concurrent combinations of anti-hypertensive drugs.
publishDate 2005
dc.date.none.fl_str_mv 2005-08-01
2015-06-14T13:31:39Z
2015-06-14T13:31:39Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S1677-55382005000400008
International braz j urol. Sociedade Brasileira de Urologia, v. 31, n. 4, p. 342-355, 2005.
10.1590/S1677-55382005000400008
S1677-55382005000400008.pdf
1677-5538
S1677-55382005000400008
http://repositorio.unifesp.br/handle/11600/2593
url http://dx.doi.org/10.1590/S1677-55382005000400008
http://repositorio.unifesp.br/handle/11600/2593
identifier_str_mv International braz j urol. Sociedade Brasileira de Urologia, v. 31, n. 4, p. 342-355, 2005.
10.1590/S1677-55382005000400008
S1677-55382005000400008.pdf
1677-5538
S1677-55382005000400008
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv International braz j urol
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 342-355
application/pdf
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268346042941440